KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Gross Margin (2016 - 2025)

Vertex Pharmaceuticals has reported Gross Margin over the past 16 years, most recently at 85.39% for Q4 2025.

  • Quarterly results put Gross Margin at 85.39% for Q4 2025, down 7.0% from a year ago — trailing twelve months through Dec 2025 was 86.24% (up 13.0% YoY), and the annual figure for FY2025 was 86.24%, up 13.0%.
  • Gross Margin for Q4 2025 was 85.39% at Vertex Pharmaceuticals, down from 86.52% in the prior quarter.
  • Over the last five years, Gross Margin for VRTX hit a ceiling of 88.85% in Q1 2021 and a floor of 85.38% in Q4 2023.
  • Median Gross Margin over the past 5 years was 87.28% (2021), compared with a mean of 87.12%.
  • Biggest five-year swings in Gross Margin: soared 79bps in 2022 and later tumbled -231bps in 2023.
  • Vertex Pharmaceuticals' Gross Margin stood at 88.06% in 2021, then fell by 0bps to 87.7% in 2022, then decreased by -3bps to 85.38% in 2023, then rose by 0bps to 85.46% in 2024, then fell by 0bps to 85.39% in 2025.
  • The last three reported values for Gross Margin were 85.39% (Q4 2025), 86.52% (Q3 2025), and 86.25% (Q2 2025) per Business Quant data.